



(51) International Patent Classification:

C07D 405/10 (2006.01) *A61K 31/70* (2006.01)
C07D 407/10 (2006.01) *A61P 3/10* (2006.01)
C07D 413/10 (2006.01)

(21) International Application Number:

PCT/EP2010/065747

(22) International Filing Date:

19 October 2010 (19.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2173/DEL/2009 20 October 2009 (20.10.2009) IN
 2689/DEL/2009 23 December 2009 (23.12.2009) IN

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEBERNITZ, Gregory, Raymond** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, MA 02139 (US). **BOCK, Mark, G.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **REDDY, Dumbala Srinivas** [IN/IN]; Alpha 605, Jayabheri Silicon County, Hi-Tec City Road Kondapur, Hyderabad, Andhra Pradesh 500 032 (IN). **HAJARE, Atul Kashinath** [IN/IN]; Plot No. 28, Sadik Mala, Mali Lane Bhingar, Ahmednagar, Maharashtra 414 002 (IN). **VYAVAHARE, Vinod** [IN/IN]; Advinus Therapeutics (P) Limited, of 21 and 22 Phase II, Peenya Industrial


Area, Bangalore 560 058 (IN). **BHOSALE, Sandeep Bhausaheb** [IN/IN]; 1385, Sambhajinagar (HUDCO), A/ P & Tal. : Shirur, Pune, Maharashtra 412 210 (IN). **KURHADE, Suresh Eknath** [IN/IN]; Lawanwadi, Post Ale, Tal. Junnar, Pune, Maharashtra 412 411 (IN). **SALUNKHE, Videsh** [IN/IN]; Advinus Therapeutics (P) Limited, of 21 and 22 Phase II, Peenya Industrial Area, Bangalore 560 058 (IN). **SHAIKH, Nadim, S.** [IN/IN]; Advinus Therapeutics (P) Limited, of 21 and 22 Phase II, Peenya Industrial Area, Bangalore 560 058 (IN). **BHUNIYA, Debnath** [IN/IN]; Post Khalisani, Howrah, West Bengal 711 037 (IN). **PALLE, P., Venkata** [IN/IN]; 24 Gera Green Ville, Survey No. 64 Kharadi, Pune, Maharashtra 411 014 (IN). **FENG, Lili** [CN/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, Bldg. 436, East Hanover, NJ 07936-1080 (US). **LIANG, Jessica** [CN/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080 (US).

(74) Agent: **CAMPBELL, Lachlan**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: GLYCOSIDE DERIVATIVES AND USES THEREOF



(I)

(57) Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*